Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer

Current Oncology

Volumn 17, Issue 1, 2010, Pages 7-16

  Mittmann, N ^a   Verma, S ^b   Koo, Marika ^a   Alloul, K ^c   Trudeau, M ^d  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c SANOFI   (France)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Adjuvant chemotherapy; Breast cancer; Cost analysis; Economic model; Prophylaxis

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; ONDANSETRON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; ANEMIA; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; QUALITY ADJUSTED LIFE YEAR; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 75849138459     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i1.445     Document Type: Review

References (23)

1. Martin M, Pienkowski T, Mackey J, et al. on behalf of the Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13.
2. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd ed. Ottawa, ON: CADTH; 2006. [Available online at: www.cadth.ca/media/pdf/186-EconomicGuidelines-e.pdf; cited December 7, 2008]
3. Aventis Pharma Research and Development. A multicenter phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus 5-fluorouracil in combination with doxorubicin and cyclophosphamide (FAC) as adjuvant treatment of operable breast cancer patients with positive axillary lymph nodes. TAX 316. Clinical study report RP56976V-316 [internal data: results of the second interim analysis at 55 months' median follow-up]. Bridgewater, NJ: Aventis Pharma Research and Development; 2004.
4. Aremis Consultants. Health Economic Model in Adjuvant Breast Cancer - Intercontinental Model: User Guide. Paris, France: Aremis Consultants; 2005.
5. Sorensen SV, Brown R, Benedict A, Flood E, Revicki D. Patient-rated utilities in postmenopausal early breast cancer (EBC): a cross-country comparison [abstract]. ISPOR Seven Annual European Congress. Value Health 2004;7:641-2.
6. Launois R, Reboul-Marty J, Henry B, Bonneterre J. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 1996;10:504-21.
7. Brown RE, Hutton J. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 1998;9:899-907.
8. Lee JH, Glick HA, Hayman JA, Solin LJ. Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients. J Clin Oncol 2002;20:2713-25.
9. Cancer Care Ontario (CCO). Home > Treatment > Cancer Drugs > Drug Formulary > Chemotherapy Regimens > Breast > Neoadjuvant or Adjuvant [Web resource]. Toronto, ON: CCO. [Available online at: www.cancercare.on.ca/toolbox/drugs/drugformulary/drugregimens/breastreg/; cited December 17, 2009]
10. Cancer Care Ontario, Program in Evidence-Based Care (PEBC). Baseline Staging Tests in Primary Breast Cancer. Practice guideline report 1-14. Toronto, ON: PEBC; 2003. [Available online at: www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=13866; cited December 17, 2009]
11. Bank of Canada. Home > Rates and Statistics > Related Information > Inflation Calculator [Web resource]. Ottawa, ON: Bank of Canada; n.d. [Available at: www.bankofcanada.ca/en/rates/inflation-calc.html; cited December 8, 2009]
12. Sunnybrook Health Sciences Centre, Department of Pharmacy. Drug Formulary. Toronto, ON: Sunnybrook Health Sciences Centre; 2008.
13. Ontario Case Costing Initiative (OCCI). Home > Costing Analysis (CAT) Tool [Web resource]. Toronto, ON: OCCI; 2005. [Available online at: www.occp.com/; cited December 8, 2009]
14. Lalami Y, Paesmans M, Aoun M, et al. A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Support Care Cancer 2004;12:725-30.
15. Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 2000;36:724-35.
16. Ontario Ministry of Health and Long-Term Care. Schedule of Benefits: Physician Services under the Health Insurance Act (July 1, 2003). Toronto, ON: Ontario Ministry of Health and Long-Term Care; 2004.
17. Martin M, Lluch A, Segui MA, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the tac regimen. Ann Oncol 2006;17:1205-12.
18. Wisconsin Department of Health and Family Services, Division of Health Care Financing, Bureau of Health Information. Wisconsin Cancer Incidence and Mortality, 1999. PHC 5328. Madison, WI: Wisconsin Case Reporting System; 2002. [Available online at: dhs.wisconsin.gov/wcrs/pdf/cainwi99.pdf; cited December 17, 2009]
19. Martin M, Lluch A, Segui M, et al. Toxicity and health-related quality of life (HRQOL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): impact of adding prophylactic growth factors (GF) to TAC. GEICAM Study 9805. Proc Am Soc Clin Oncol 2005;23:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst- detail-view&confID=34&abstractID=31076; cited December 8, 2009]
20. Aventis Pharma Research and Development. A Multicenter Phase iii Randomized Trial Comparing Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAC) Versus 5-Fluorouracil in Combination with Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of High-Risk Operable Breast Cancer Subjects with Negative Axillary Lymph Nodes. TAX.ES1.301 (GEICAM 9805). Interim clinical study report (safety findings only) for June 1999-March 2003 [internal data]. Bridgewater, NJ: Aventis Pharma Research and Development; 2006.
21. Au HJ, Golmohammadi K, Younis T, et al. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the down-stream effects. Breast Cancer Res Treat 2009;114:579-87.
22. Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol 2008;26:925-33.
23. Younis T, Rayson D, Sellon M, Skedgel C. Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Res Treat 2008;111:261-7.